Pallavi Jha, New Delhi: Leading vaccine producer Bharat Biotech has introduced that it has efficiently developed Covicin, India’s first vaccine candidate for COVID-19 in affiliation with Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).
Human trials for this potential coronavirus vaccine will begin next month.
A press release issued by the company mentioned that the SARS-COV-2 pressure was remoted on the NIV based mostly in Pune and transferred to Bharat Biotech. The home, inactivated vaccine was developed and manufactured at Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment Facility positioned in Gnome Valley, Hyderabad.
The Drug Controller General of India, Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare have given permission to start out the Phase 1 and Phase 2 human medical trials. Prior to this, the company had submitted the outcomes obtained from pre-clinical research.
“We are proud to announce India’s first domestically developed vaccine, Kovaxin, against Kovid-19. ICMR and NIV have been instrumental in the development of this vaccine. The project was approved with the active support and guidance of CDSCO. Our R&D and manufacturing teams worked tirelessly towards this platform in the deployment of our own technologies,” Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech mentioned.